Trial Profile
Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Apatinib as a Single Agent in Advanced NSCLC Who Failed to at Least Two Lines Systemic Treatment, or Were Not Amendable to Receive the Second-line Standard Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Aug 2019
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 18 Oct 2017 Status changed to discontinued as per results presented at the 18th World Conference on Lung Cancer
- 18 Oct 2017 Results reporting updated efficacy and safety data, as well as the clinical benefit of continuing apatinib beyond initial progression presented at the 18th World Conference on Lung Cancer
- 15 Aug 2017 Status changed from recruiting to active, no longer recruiting.